• Refine Query
  • Source
  • Publication year
  • to
  • Language
  • 28
  • 27
  • 5
  • 3
  • 3
  • 2
  • 2
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • Tagged with
  • 90
  • 83
  • 25
  • 22
  • 22
  • 19
  • 18
  • 17
  • 16
  • 16
  • 14
  • 12
  • 11
  • 11
  • 10
  • About
  • The Global ETD Search service is a free service for researchers to find electronic theses and dissertations. This service is provided by the Networked Digital Library of Theses and Dissertations.
    Our metadata is collected from universities around the world. If you manage a university/consortium/country archive and want to be added, details can be found on the NDLTD website.
61

Kinase pathways underlying muscarinic activation of colonic longitudinal muscle

Anderson, Charles Dudley, Jr. 22 April 2011 (has links)
The longitudinal muscle layer in gut is the functional opponent to the circular muscle layer during the peristalsis reflex. Differences in innervation of the layers allow for the contraction of one layer that corresponds with the simultaneous relaxation of the other, enabling the passage of gut contents in a controlled fashion. Differences in development have given the cells of the two layers differences in receptor populations, membrane lipid handling, and calcium handling profiles/behaviors. The kinase signaling differences between the two layers is not as well characterized. Upon activation of cells from the circular muscle layer, it is known that Rho kinase and ERK1/2 promote contraction, while CaMKK/AMPK and CaMKII perform inhibitory/self-inhibitory roles. Such behaviors are poorly understood in the longitudinal muscle layer. In longitudinal muscle strips, we measured muscarinic receptor-mediated contraction following incubation with kinase inhibitors. Upon comparison to control, contributions of Rho Kinase and ERK1/2 were similar to those seen in circular muscle. Inhibition of both of these enzymes leads to diminished contraction. However, CaMKK/AMPK and CaMKII have effects in longitudinal muscle opposite to their regulation in circular muscle – their inhibition also diminishes the contractile response. These contractile data from strips were supported by immunokinase assay measurements of MLCK activity from strip homogenates with and without kinase inhibition. Therefore, we suggest that the activities of CaMKK/AMPK and CaMKII in longitudinal muscle are indeed different from their regulatory roles in circular muscle, perhaps a consequence of the different calcium handling modalities of the two muscle types.
62

Cirkadiánní regulace proteinu STAT3 v SCN a vliv leptinu na jeho aktivaci v SCN, v jiných částech hypotalamu a epifýze / Circadian regulation of STAT3 protein in the SCN and it's activation by leptin in the SCN, other parts of hypothalamus and the pineal gland

Moníková, Veronika January 2015 (has links)
JAK/STAT signaling pathway is one of the most studied intracellular cascades transmitting signals from the extracellular environment to the cell nucleus in order to affect expression of target genes. Circadian clocks localized in the suprachiasmatic nuclei (SCN) of the hypothalamus are sensitive especially to light but they can respond to non-photic stimuli such as growth factors, opioids, leptin and cytokines that have been demonstrated to perform its function via the JAK/STAT signaling pathway. The recent findings of our laboratory demonstrated that STAT3 protein is highly produced by SCN of rat. Primary aim of our experiments was to test the circadian regulation of STAT3 production in SCN and describe the effect of exogenously administered leptin on STAT3 phosphorylation in the SCN, pineal gland and hypothalamic structures responsible for regulated feeding behavior and energy metabolism. Because activation of leptin receptors may stimulate a number of other signaling cascades, we chose phosphorylated forms of kinase ERK1/2 and GSK-3β as other markers of intracellular changes after administration of leptin in the studied structures. Our results proved rhythmic production of STAT3 protein in SCN of rat and indicated circadian regulation of sensitivity to leptin in hypothalamic structures. The data...
63

La voie ERK1/2 : point d'intégration et de convergence des connexions entre voies de signalisation dans les cellules épithéliales de prostate normale

Poncet, Nadège 14 December 2010 (has links) (PDF)
Le développement et l'homéostasie cellulaire de la prostate impliquent le contrôle strict des voies de signalisation induites par les androgènes et les facteurs de croissance. Ces diverses voies sont profondément altérées dans le cancer de la prostate, notamment lors des stades les plus avancés. Dans ce travail, une lignée immortalisée à partir de l'épithélium de prostate humaine, la lignée RWPE-1, a été utilisée pour étudier certains signaux régulant la prolifération cellulaire, ainsi que les connexions entre les voies de signalisation correspondantes. La prolifération des cellules RWPE-1 est sous la dépendance de l'EGF (Epidermal Growth Factor) qui intervient physiologiquement dans le développement épithélial. Les récepteurs apparentés à l'EGF-R sont également impliqués dans la prolifération au cours de la progression tumorale. La prolifération des cellules RWPE-1 en réponse à l'EGF est strictement dépendante de la voie ERK1/2, qui est donc considérée comme un point d'intégration des signaux. L'utilisation d'inhibiteurs du récepteur aux androgènes a permis de montrer le rôle essentiel qu'il joue dans l'activation d'ERK1/2 en réponse à l'EGF. Le récepteur aux androgènes s'associe avec plusieurs molécules de signalisation dans les cellules RWPE-1. Je démontre ici pour la première fois une association entre le récepteur aux androgènes et la kinase Raf-1, activatrice de la voie ERK1/2. Ainsi, le récepteur aux androgènes contrôlerait directement un processus essentiel à la prolifération épithéliale selon un mode d'action non-génomique. Par ailleurs, j'ai montré que la réponse proliférative des cellules RWPE-1 à l'IL-6 requiert l'activation de la voie ERK1/2, et l'activité kinase de l'EGF-R, suggérant la transactivation de ce récepteur par l'IL-6. L'utilisation de divers inhibiteurs chimiques a permis de démontrer que les métalloprotéases de la famille ADAM (a disintegrin and metalloprotease), notamment ADAM17, sont impliquées dans ce processus. Ainsi, l'activation de protéines ADAM par l'IL-6 conduirait au clivage d'un ligand membranaire de l'EGF-R, aboutissant à l'activation de la voie ERK1/2. Ce nouveau mécanisme pourrait être impliqué dans les situations inflammatoires conduisant à une prolifération excessive de l'épithélium prostatique, prélude à la transformation tumorale. En conclusion, les voies de signalisation étudiées sont fortement connectées dans les cellules épithéliales normales. Les deux nouveaux mécanismes décrits ici aboutissent à l'activation des kinases ERK1/2, point d'intégration et de convergence des voies de signalisation dans les cellules épithéliales de prostate normale.
64

Regulación de CREB y deltaFosB en el sistema cerebral del estrés durante la exposición crónica a morfina

Martín Sánchez, Mª Rosario Fátima 08 July 2011 (has links)
Tesis por compendio / La exposición crónica a sustancias de abuso lleva a cambios adaptativos en el cerebro que implican alteraciones en la expresión génica. Se ha propuesto que los factores de transcripción CREB y deltaFosB serían dianas moleculares para la regulación de la plasticidad, la cual lleva a la adicción.En este trabajo hemos estudiado los cambios en la activación de CREB, en PVN y NTS, y las quinasas que mediarían su activación durante la dependencia y síndrome de abstinencia a morfina, así como la respuesta del eje HHA durante dicho síndrome. También se investigó la posibilidad de que la activación de CREB y su coactivador transcripcional TORC1 dependan de la activación de receptores adrenérgicos. Además se evaluaron las posibles modificaciones en la expresión de FosB/deltaFosB en diferentes áreas cerebrales implicadas en la adicción, así como los cambios neuroendocrinos/neuroquímicos responsables de las alteraciones metabólicas observadas durante el tratamiento crónico con morfina. / Chronic exposure to opioids and other abused drugs results in adaptive changes in the brain involving alterations in gene expression. It is proposed that the transcription factors CREB and deltaFosB be molecular targets for the regulation of plasticity, which leads to addiction.In this work we studied changes in activation of the cAMP-response element binding protein (CREB) in PVN and NTS and the kinases that may mediate this activation during dependence and morphine withdrawal and the HPA axis response after naloxone-induced morphine withdrawal. We also investigated the possibility that the activation of CREB and the transcriptional coactivator of CREB, TORC1, arises from the activation of adrenergic receptors. We also evaluated the possible modifications in FosB/deltaFosB expression in several brain areas involved in addiction and neuroendocrine/neurochemical changes that are responsible for the metabolic alterations seen during chronic morphine treatment.
65

Couplage du récepteur à sept domaines transmembranaires GABA-B1 aux voies intracellulaires de signalisation en absence de GABA-B2

Richer, Maxime 02 1900 (has links)
Le GABA est le principal neurotransmetteur inhibiteur du SNC et est impliqué dans le développement du cerveau, la plasticité synaptique et la pathogénèse de maladies telles que l’épilepsie, les troubles de l’anxiété et la douleur chronique. Le modèle actuel de fonctionnement du récepteur GABA-B implique l’hétérodimérisation GABA-B1/B2, laquelle est requise au ciblage à la surface membranaire et au couplage des effecteurs. Il y est cependant des régions du cerveau, des types cellulaires et des périodes du développement cérébral où la sous-unité GABA-B1 est exprimée en plus grande quantité que GABA-B2, ce qui suggère qu’elle puisse être fonctionnelle seule ou en association avec des partenaires inconnus, à la surface cellulaire ou sur la membrane réticulaire. Dans le cadre de cette thèse, nous montrons la capacité des récepteurs GABA-B1 endogènes à activer la voie MAPK-ERK1/2 dans la lignée dérivée de la glie DI-TNC1, qui n’exprime pas GABA-B2. Les mécanismes qui sous-tendent ce couplage demeurent mal définis mais dépendent de Gi/o et PKC. L’immunohistochimie de récepteurs endogènes montre par ailleurs que des anticorps GABA-B1 dirigés contre la partie N-terminale reconnaissent des protéines localisées au RE tandis des anticorps C-terminaux (CT) marquent une protéine intranucléaire. Ces données suggèrent que le domaine CT de GABA-B1 pourrait être relâché par protéolyse. L’intensité des fragments potentiels est affectée par le traitement agoniste tant en immunohistochimie qu’en immunobuvardage de type western. Nous avons ensuite examiné la régulation du clivage par le protéasome en traitant les cellules avec l’inhibiteur epoxomicine pendant 12 h. Cela a résulté en l’augmentation du marquage intranucléaire de GABA-B1-CT et d’un interacteur connu, le facteur de transcription pro-survie ATF-4. Dans des cellules surexprimant GABA-B1-CT, l’induction et la translocation nucléaire d’ATF-4, qui suit le traitement epoxomicine, a complètement été abolie. Cette observation est associée à une forte diminution du décompte cellulaire. Étant donné que les trois derniers résidus de GABA-B1-CT (LYK) codent un ligand pseudo-PDZ et que les protéines à domaines PDZ sont impliquées dans la régulation du ciblage nucléaire et de la stabilité de protéines, en complément de leur rôle d’échaffaud à la surface cellulaire, nous avons muté les trois derniers résidus de GABA-B1-CT en alanines. Cette mutation a complètement annulé les effets de GABA-B1-CT sur l’induction d’ATF-4 et le décompte cellulaire. Cette deuxième série d’expériences suggère l’existence possible de fragments GABA-B1 intranucléaires régulés par le traitement agoniste et le protéasome dans les cellules DI-TNC1. Cette régulation d’ATF-4 dépend des résidus LYK de GABA-B1-CT, qui modulent la stabilité de GABA-B1-CT et favorisent peut-être la formation d’un complexe multiprotéique incluant GABA-B1-CT, ATF-4, de même qu’une protéine d’échaffaudage inconnue. En somme, nous démontrons que les sous-unités GABA-B1 localisées au RE, lorsque non-hétérodimérisées avec GABA-B2, demeurent capables de moduler les voies de signalisation de la prolifération, la différentiation et de la survie cellulaire, via le couplage de protéines G et possiblement la protéolyse régulée. Les mécanismes de signalisation proposés pourraient servir de nouvelle plate-forme dans la compréhension des actions retardées résultant de l’activation des récepteurs 7-TMs. / GABA is the principal inhibitory neurotransmitter in the CNS and is implicated in brain development, synaptic plasticity and the pathogenesis of diseases such as epilepsy, anxiety disorders and chronic pain. In the current model of GABA-B function, there is a requirement for GABA-B1/B2 dimerization for targetting to the cell surface and effector coupling. However, there are certain brain regions (putamen), cell types (glial cells) and times during brain development where GABA-B1 is expressed in higher amounts than GABA-B2, suggesting that GABA-B1 might be functional alone or in association with unidentified partners, either at the cell surface or on the ER membranes. In this thesis, we first show the capacity of endogenous GABA-B1 receptors to activate the MAPK-ERK1/2 pathway in the DI-TNC1 glial-derived cell line which does not express GABA-B2. The underlying mechanisms remain incompletely defined but depend on Gi/o and PKC. Immunohistochemistry of endogenous receptors shows that GABA-B1 N-terminal antibodies recognize ER-localized proteins and that C-terminal (CT) antibody shows intranuclear distribution. This data suggests that fragments of the GABA-B1 receptor are generated by proteolysis and indeed we show that agonist treatment affects the intensity of certain C-terminal GABA-B1 fragments both in immunohistochemistry and western blots suggesting that the GABA-B1 receptor is subjected to regulated proteolysis. Since a 13-residue potential PEST sequence was localized immediately distal to the ER retention motif in the GABA-B1 CT, we examined proteasome regulation of the cleavage event. Following a 12h treatment with the proteasome inhibitor, epoxomicin, we detected increases in intranuclear staining for both GABA-B1 and a known interactor, the pro-survival transcription factor ATF-4, using confocal microscopy and by western blotting of nuclear extracts. These increases are due either to proteasome inhibition or activation of the ER stress pathway. In cells overexpressing GABA-B1-CT, ATF-4 induction and nuclear translocation, which normally follows epoxomicin treatment, was completely abolished. This observation was associated to a strong decrease in cell number. Since the last three residues of GABA-B1-CT (LYK) encode a pseudo-PDZ ligand and that PDZ domain protein regulate nuclear targeting and protein stability, in complement to their role in scaffolding at the cell surface, we mutated the last three residues of GABA-B1-CT to alanines. This mutation completely reversed the effect of GABA-B1-CT on ATF-4 induction and on cell number. This second set of data suggests the existence of agonist and proteasome-regulated intranuclear GABA-B1 fragments in DI-TNC1 cells. Further, the GABA-B1-CT pseudo-PDZ ligand appears to be critically important in regulating ATF-4 induction by modulating GABA-B1-CT stability and perhaps by favoring the formation of a multiprotein complex with ATF-4, ATF-4 interactors and an unknown scaffolding protein. Overall, we show that ER-localised GABA-B1 subunits, when not dimerized with GABA-B2, can still modulate proliferation, differentiation and survival pathways, both through G-protein coupling and regulated proteolysis. The signalling mechanisms which we propose could serve as a new platform in understanding the long term effects of 7-TM receptor activation.
66

Mécanisme d’action du PBI-1402 impliqué dans l’expansion des progéniteurs érythroïdes humains et murins

Vinet, Sabrina 08 1900 (has links)
Une des complications importantes d’un traitement intensif de chimio/radio-thérapie est l’aplasie de la moelle osseuse qui peut persister longtemps même après une greffe de cellules souches. Le PBI-1402 est un petit lipide qui a été associé à la diminution de l’apoptose des neutrophiles induite par des agents cytotoxiques. Nos travaux ont démontré que la culture in vitro de progéniteurs hématopoiétiques humains en présence de PBI-1402 induit une augmentation significative du nombre de progéniteurs érythroides (PEryth) (p<0,05). En évaluant la sensibilité des PEryth à l’érythropoietine (Epo), nous avons démontré que le PBI-1402 n’a pas d’effet sensibilisateur et que les cellules répondent de façon similaire aux cellules contrôles. De plus, la combinaison de l’Epo et du « stem cell factor » avec le PBI-1402 permet de prolonger et d’augmenter l’activation d’ERK1/2 (p<0,05), un important signal mitogène. Cet effet est associé à une inhibition de l’activation de la phosphatase MKP-1 dans les cellules exposées au PBI-1402. Nous démontrons aussi la capacité du PBI-1402 à amplifier la prolifération des PEryth et sa capacité à réduire la durée et l’intensité de l’anémie dans un modèle in vivo murin. Des souris ayant reçu une dose létale d’irradiation et subi une transplantation syngénique de moelle osseuse, ont été traitées oralement avec le PBI-1402 pendant 14 jours. Ces souris démontrent une réduction significative de l’anémie post-transplantation versus les souris contrôle (p<0,05). De plus, la moelle osseuse des souris traitées au PBI-1402 présente un nombre de BFU-E et CFU-E plus élevé comparativement au contrôle. Ces résultats démontrent donc le potentiel du PBI-1402 à réduire l’anémie post-transplantation et accélérer la reconstitution érythroïde. / One of the most important complications of intensive radiotherapy or chemotherapy is cytopenia, which can persist for significant amount of time even after stem cell transplantation. PBI-1402, a small lipid, was previously shown to be associated with decreased neutrophil apoptosis caused by cytotoxic agents. Our work has shown that day primary human hematopoietic cell in vitro culture in the presence of PBI-1402 resulted in an increased number of erythroid progenitors (p<0,05). Dose-response experiments evaluating sensitivity to erythropoietin (Epo) of cells exposed to PBI-1402 indicated that PBI-1402 did not have a sensitizing effect and that both treated and control cells respond similarly to Epo. In addition, PBI-1402, used in combination with stem cell factor (SCF) and Epo, enhanced and prolonged ERK1/2 phosphorylation (p<0.05), a signalling pathway important for erythroid progenitor cell proliferation. This effect was associated with a decrease of the phosphatase MKP-1 activation in PBI-1402 exposed cells. This translated into and increased proliferation of erythroid progenitors as well as a reduced duration and level of anemia in an in vivo murine transplantation model. Lethally irradiated mice that received syngeneic stem cell transplantation were treated orally with PBI-1402 for 14 days. These mice demonstrated a significant reduction in post-transplantation anemia in a dose dependent manner compared to control (vehicle)(p<0.05). Moreover, PBI-1402-treated mice harboured significantly higher numbers of BFU-E and CFU-E in bone marrow compared to control (p<0.05). These results demonstrate that PBI-1402 treatment significantly reduced transplantation-induced anemia with concomitant acceleration in erythroid recovery.
67

Imidazoline receptor antisera-selected protein: a unique modulator of neuronal differentiation.

Dehle, Francis Christian January 2008 (has links)
The imidazoline I1 receptor (I1-R) is a novel receptor found primarily in the brain and nervous tissue where it modulates neurotransmission. It is named for its high affinity for compounds with an imidazoline structure such as the anti-hypertensive drugs, clonidine and moxonidine. The imidazoline receptor antisera-selected protein (IRAS) is the putative clone of the I1-R. IRAS has a unique structure, which does not resemble any other receptor protein. IRAS is present throughout the body with highest levels in the brain. There is a growing body of research examining the physiological roles of IRAS as an I1-R, in cell survival, migration and protein trafficking. However, there is little research into its neuronal functions. IRAS interacts with other membrane receptors: the mouse homologue of IRAS reorganises the actin cytoskeleton through interaction with the α5β1 fibronectin receptor. IRAS also binds insulin receptor substrate 4 and enhances insulin-induced extracellular signal-regulated kinase1/2 (ERK1/2) activation. Actin reorganisation and ERK1/2 activation are important for the development of neurites during neuronal differentiation. Therefore, the work described in this thesis aimed to investigate the effects of IRAS on neuronal differentiation. Studies reported in this thesis also aimed to investigate whether IRAS affected ERK1/2 signalling of other receptors involved in neuronal differentiation such as the NGF receptor, TrkA, and lysophospholipid receptors. The above aims were carried out in neuronal model PC12 cells transfected with either IRAS or a vector plasmid. Fluorescence microscopy and Western blotting techniques were used to examine the effect of IRAS on cell morphology and ERK1/2 signalling. The work described in this thesis found that IRAS reorganises the actin cytoskeleton and enhances growth cone development in PC12 cells. This study also shows that IRAS differentially enhances or inhibits NGF-induced PC12 cell differentiation depending on the presence or absence of serum in the media. In full-serum conditions, IRAS enhanced neurite outgrowth and this was accompanied by an increase in ERK1/2 activation. In serum-starved cells, IRAS inhibited neurite outgrowth with similar levels of ERK1/2 activation observed in vector- and IRAS-transfected cells. Finally, studies presented in this thesis found that IRAS enhances lysophosphatidic acid-induced ERK1/2 activation and that IRAS interacting with lysophospholipid receptor agonists present in serum is a potential mechanism by which it enhances NGF-induced ERK1/2 activation in full-serum conditions. / http://proxy.library.adelaide.edu.au/login?url= http://library.adelaide.edu.au/cgi-bin/Pwebrecon.cgi?BBID=1345359 / Thesis (Ph.D.) - University of Adelaide, School of Medical Sciences, 2008
68

Efeitos do alfa-tocoferol (vitamina E) na hematopoese murina por mecanismos não-antioxidantes / Effects of alpha-tocopherol (vitamin E) on murine hematopoiesis by non-antioxidant mechanisms

Nogueira-Pedro, Amanda [UNIFESP] 30 September 2009 (has links) (PDF)
Made available in DSpace on 2015-07-22T20:49:58Z (GMT). No. of bitstreams: 0 Previous issue date: 2009-09-30. Added 1 bitstream(s) on 2015-08-11T03:25:27Z : No. of bitstreams: 1 Publico-00264.pdf: 1668171 bytes, checksum: dbdf365617164c11a9a209e69d18f997 (MD5) / O ƒÑ-tocoferol tem sido o foco das pesquisas dentre os demais componentes da vitamina E por ser a forma predominantemente encontrada nos tecidos de mamiferos, e por possuir uma extensa gama de atividades biologicas. O ƒÑ-tocoferol pode atuar como regulador de enzimas especificas e de fatores de transcricao de forma a influenciar estruturas celulares como membranas e dominios lipidicos, desencadeando respostas celulares que muitas vezes se mostram independentes de sua funcao antioxidante. No sistema hematopoetico, seus efeitos foram favoraveis em casos de anemias hemoliticas, aumentando a resistencia dos eritrocitos a lise. Tambem foi observado que a suplementacao previa com ƒÑ-tocoferol a irradiacao resulta em aumento da sobrevida de camundongos por induzir aumento no numero de unidades formadoras de colonias (CFUs). Entretanto, os mecanismos biologicos ativados pelo ƒÑ-tocoferol nas celulas hematopoeticas ainda nao foram descritos. Assim, os bjetivos deste trabalho foram verificar os efeitos do ƒÑ-tocoferol na hematopoese murina e os mecanismos intracelulares relacionados a estes efeitos. Para tal, camundongos foram tratados intraperitonealmente com doses de 40 mg/kg/dia de ƒÑ-tocoferol durante 2 semanasem dias intercalados, sendo sacrificados 24 horas apos a ultima dose; condicoes estas que nao causaram toxicidade as celulas da medula ossea. Amostras histologicas dos femures dos animais que receberam o tratamento com ƒÑ-tocoferol apresentaram hiperplasia medular. O tratamento com ƒÑ-tocoferol induziu aumento na porcentagem das celulas progenitoras hematopoeticas (Lin-Sca-1+c-Kit+ e Lin-Sca-1-c-Kit+), assim como o aumento do estado proliferativo destas populacoes (com mais celulas primitivas na fase S/G2/M do ciclo celular), com o consequente aumento da capacidade de formar CFUs de granulocitos e macrofagos. Dentre as distintas populacoes de celulas maduras da medula ossea, houve um favorecimento da linhagem granulocitica/monocitica (Mac-1+Gr-1+) em detrimento das linhagens eritrociticas (Ter119+) e linfociticas (B220+ e CD3+). Como forma de avaliar o mecanismo de acao do ƒÑ-tocoferol, investigou-se tambem a ativacao das proteinas relacionadas com a sinalizacao das celulas hematopoeticas. Assim, observou-se que as populacoes primitivas medulares apresentaram uma menor ativacao da cinase regulada por sinais extracelulares 1/2 (ERK1/2), da proteina cinase C (PKC), do ¡§ativador de transcricao e transdutor de sinal ¡V 5¡§ (STAT-5), mas nao da proteina cinase B/Akt. Tambem foi verificado que a diminuicao do estado fosforilado da ERK1/2 ocorreu desde os primeiros dias de tratamento. Interessante destacar quer o ƒÑ-tocoferol potencializou o efeito da interleucina-3 (IL-3) sobre a ativacao da ativacao da ERK1/2 nas celulas primitivas hematopoeticas. O inibidor da MEK (PD98059) foi capaz de restabelecer as porcentagens normais das linhagens eritrocitica e granulocitica/monocitica, assim como os niveis normais da fosfo- ERK1/2, alem da resposta da ERK1/2 ao estimulo com IL-3. Entretanto, o PD98059 nao restabeleceu as porcentagens normais das celulas primitivas hematopoeticas, nem da linhagem linfocitica. A quantificacao das especies reativas de oxigenio nas diferentes populacoes da medula ossea mostrou que, nas condicoes de tratamento estabelecidas, o ƒÑ-tocoferol nao exerceu funcao proou antioxidante, pois nao houve alteracao significativa dos niveis de especies reativas de oxigenio entre os grupos controle e tratado com ƒÑ-tocoferol. Desta forma, foi mostrada uma nova propriedade do ƒÑ-tocoferol independente de sua acao redox: a inducao de hiperplasia na medula ossea pelo aumento dos progenitores hematopoeticos e favorecimento da diferenciacao destes em granulocitos e macrofagos, pela potencializacao da resposta da ERK1/2 ao estimulo com IL-3. / TEDE / BV UNIFESP: Teses e dissertações
69

Erk1 and Erk2 in hematopoiesis, mast cell function, and the management of Nf1-associated leukemia and tumors

Staser, Karl W. 07 August 2012 (has links)
Indiana University-Purdue University Indianapolis (IUPUI) / Neurofibromatosis type 1 is a genetic disease that results from either heritable or spontaneous autosomal dominant mutations in the NF1 gene, which encodes a protein serving, at least in part, to accelerate the intrinsic hydrolysis of active Ras-GTP to inactive Ras-GDP. A second-hit NF1 mutation precedes predominant NF1 neoplasms, including juvenile myelomoncytic leukemia (JMML) and plexiform neurofibroma formation, potentially fatal conditions with no medical therapy. While NF1 loss of heterozygosity (LOH) in myeloid progenitor cells sufficiently engenders leukemogenesis, plexiform neurofibroma formation depends on LOH in Schwann cells and Nf1 heterozygosity in the hematopoietic system. Specifically, recruited Nf1+/- mast cells accelerate tumorigenesis through secreted cytokines and growth factors. Nf1+/- mast cells depend upon deregulated signaling in c-kit pathways, a receptor system conserved in hematopoietic stem cells (HSCs). Accordingly, Nf1-/- myeloid progenitor cells, which can induce a JMML-like disease in mice, also demonstrate deregulated c-kit receptor signaling. C-kit-activated Nf1+/- mast cells and Nf1-/- myeloid progenitors both show increased latency and potency of active Erk1 and Erk2, the principal cytosolic-to-nuclear effectors of canonical Ras-Raf-Mek signaling. Thus, Erk represents a potential regulator of leukemogenesis and tumor-associated inflammation. However, single and combined Erk1 and Erk2 roles in HSC function, myelopoiesis, and mature mast cell physiology remain unknown, and recent hematopoietic studies relying on chemical Mek-Erk inhibitors have produced conflicting results. Here, we show that hematopoietic stability, myelopoiesis, and mast cell generation require Erk1 or Erk2, but individual isoforms are largely dispensable. Principally, Erk-disrupted hematopoietic stem cells incorporate BrdU but are incapable of dividing, a novel and cell type-specific Erk function. Similarly, mast cell proliferation requires Erk but cytokine production proceeds through other pathways, elucidating molecule-specific functions within the c-kit cascade. Based on these findings, we have reduced tumor mast cell infiltration by treating genetically-engineered tumor model mice with PD0325901, a preclinical Mek-Erk inhibitor. Moreover, we have devised a quadruple transgenic HSC transplantation model to examine dual Erk disruption in the context of Nf1 nullizygosity, testing whether diseased hematopoiesis requires Erk. These insights illuminate cell-specific Erk functions in normal and Nf1-deficient hematopoiesis, informing the feasibility of targeting Mek-Erk in NF1-associated disease.
70

Neuroprotection and regeneration of adult lesioned retinal ganglion cells by the modulation of fibroblast growth factor-2 and receptor tyrosine phosphatase-sigma

Sapieha, Przemyslaw (Mike) January 2005 (has links)
Thèse numérisée par la Direction des bibliothèques de l'Université de Montréal.

Page generated in 0.0714 seconds